NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Exelixis, Inc. (EXEL) Stock Analysis

Exelixis, Inc. (EXEL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

EXEL

$59.01

−$0.12 (−0.20%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EXEL with… →

EXEL Key Statistics

As of Sep 4, 2026
Trading
Open
$58.50
Previous Close
$59.13
Day's Range
58.46–59.26
52-Week Range
33.76–59.72
Volume
1.58M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.42
Valuation
Market Cap
$14.62B
P/E Ratio
18.62
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
13.85
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.56
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.00
EPS (ttm)Profit attributable to each share over the last twelve months.
3.17
Financials (FY)
Revenue (FY)
$2.32B+6.98%
Net Income (FY)
$782.57M+50.13%
Profit marginThe share of revenue left as profit after all costs and taxes.
35.33%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
247.78M
1-Year Return
+57.87%
Dividend and dates
Earnings Date
October 27, 2026
Avg Volume
2.56M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

EXEL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+34.63%
2025+31.62%
2024+38.81%
2023+49.56%
2022−12.25%
2021−8.92%
2020+13.90%
2019−10.42%
2018−35.30%
2017+103.89%
2016 (partial year)+36.41%

As of September 4, 2026.

EXEL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.32B$782.57M33.7%
2024$2.17B$521.27M24.0%
2023$1.83B$207.77M11.4%
2022$1.61B$182.28M11.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.32B$2.24B$892.70M$782.57M33.7%
2024$2.17B$2.09B$689.95M$521.27M24.0%
2023$1.83B$1.76B$170.89M$207.77M11.4%
2022$1.61B$1.55B$201.48M$182.28M11.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EXEL Valuation vs Biotechnology Median

Median of 656 stocks
MetricEXELBiotechnology medianvs median
P/E18.6212.5748% above
P/S ratio6.0015.2661% below
Profit margin35.33%0.00%35.3 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Exelixis, Inc. (EXEL) at $14.62B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 1,077.

The most recent close on file for EXEL is $59.01, dated September 4, 2026. That is −$0.12 (−0.20%) against the previous close. The 52-week range on file runs from $33.76 to $59.72. The latest close sits 74.79% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $2.32B. That is +6.98% against the prior fiscal year, when revenue was $2.17B. The same year closed with net income of $782.57M. That is +50.13% against the prior fiscal year. Profit margin runs at 35.33%. That is 35.3 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 3.17.

Across the 4 fiscal years on file, revenue moves from $1.61B in 2022 to $2.32B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 18.62 times earnings. That is 48.13% above the Biotechnology median of 12.57. The forward P/E on file is 13.85. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.56. Measured against sales, the shares trade at 6 times revenue. On price-to-sales that is 60.67% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +57.87%. Across 10 years the annualized return works out at +17.73%. Beta against the wider market is reported at 0.42. Annualized volatility over the trailing 10 years is 44.16%.

Growth & Income

No dividend is on file for EXEL.

The strongest complete calendar year on file is 2017 at +103.89%; the weakest is 2018 at −35.30%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is +34.63% year to date.

Peer Comparison

Exelixis, Inc. (EXEL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Exelixis, Inc. EXEL $14.62B 18.6
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Exelixis, Inc. trades at a P/E of 18.6.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Exelixis, Inc.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Visit website →